Related Experiment Videos
Familial hypertryptophanemia in two siblings
J R Martin1, C S Mellor, F C Fraser
1Discipline of Medicine, Memorial University, St. John's Newfoundland, Canada.
Clinical Genetics
|April 1, 1995
Summary
Two siblings with hypertryptophanemia and tryptophanuria exhibited intellectual disability and mood disorders. Their family history suggests an autosomal recessive genetic cause for this rare metabolic disorder.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Hypertryptophanemia is a rare metabolic disorder characterized by elevated tryptophan levels in the blood.
- Tryptophanuria, the excretion of excess tryptophan in urine, often accompanies hypertryptophanemia.
- Understanding the genetic basis of such disorders is crucial for diagnosis and potential therapeutic strategies.
Observation:
- Two siblings presented with mild to moderate intellectual disability, significant mood fluctuations, and behavioral changes including apparent hypersexuality.
- Specific clinical features in the male sibling included severe myopia, speech difficulties, musculoskeletal issues, and heightened sensory perception.
- The sister exhibited deafness, attributed to prenatal rubella, highlighting potential co-occurring conditions or distinct genetic influences.
Findings:
- The co-occurrence of hypertryptophanemia and tryptophanuria in siblings, along with affected family members, points towards a genetic etiology.
- Abnormal tryptophan metabolite levels in the mother and a half-sibling support a pattern consistent with autosomal recessive inheritance.
- The variable expression observed in heterozygotes suggests complex genetic or environmental interactions influencing phenotype.
Implications:
- This study identifies a potential genetic link between tryptophan metabolism and neurodevelopmental and behavioral disorders.
- The findings underscore the importance of metabolic screening in individuals with unexplained intellectual and affective disturbances.
- Further research into the specific gene(s) and molecular pathways involved could pave the way for targeted interventions for hypertryptophanemia and related conditions.